Cardinal Health (CAH) AI Stock Analysis
Cardinal Health
(BMV:CAH)
No summary available
Cardinal Health (CAH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 58.00B
- Dividend Yield
- 0.77%
- Average Volume (3M)
- 873
- Price to Earnings (P/E)
- 34.5
- Beta (1Y)
- -0.23
- Revenue Growth
- 4.02%
- EPS Growth
- 2.08%
- Country
- Mexico
- Employees
- 61,344
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Cardinal Health Business Overview & Revenue Model
Company Description
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse c...
Cardinal Health Earnings Call Summary
The call emphasized strong, broad-based fiscal '26 performance across revenue, profit, EPS (Q4 EPS +40% YoY) and cash flow ($5B adjusted FCF), with clear operational momentum in Pharma, Specialty and Other growth businesses and disciplined capital return (share buybacks and increased repurchase authorization). Key risks highlighted include reliance on a nonrecurring $100M IEEPA tariff refund that materially boosted GMPD profitability and $0.31 of Q4 EPS, input cost pressures (fuel and commodity resins), regulatory headwinds (IRA/340B impacts ~500 bps mentioned), and expected near-term cadence softness (Q1 FY27 headwind). Overall, positives around scale, cash generation, segment momentum and reconfirmed long‑term targets materially outweigh the transitory and manageable challenges discussed.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Cardinal guided fiscal 2027 non‑GAAP EPS of $12.40–$12.60 (13–15% growth off a $10.95 baseline that excludes the $0.31 IEEPA tariff benefit) and reconfirmed long‑term EPS growth of 12–14% per year; segment guidance calls for Pharma revenue growth of 3–5% and Pharma profit growth of 8–11% (with 2–3 percentage points of profit contribution from announced M&A and Q1 Pharma profit expected near the high end due to Solaris), GMPD revenue growth of 2–4% and segment profit of $200–$220 million (≈$50M growth ex‑IEEPA, H2‑weighted with Q1 roughly half of prior Q1 on FX and purchase timing), and Other businesses revenue growth of 11–13% with profit up 15–18% (including ~2 points of profit from the Strive and AdaptHealth tuck‑ins); below the line, interest and other expense is expected to be $240–$290M, the effective tax rate 19–20%, adjusted free cash flow $3.5–$4.0B, CapEx ~$700M, at least $1B of share repurchases (implying ~233M diluted shares), no material M&A assumed but modest tuck‑in capacity retained, and liquidity supported by a new $4B revolver.
Cardinal Health Risk Analysis
Cardinal Health disclosed 13 risk factors in its most recent earnings report. Cardinal Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCardinal Health Peers Comparison
Overall Rating
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:CAH | Cardinal Health | 4671.00 | 1758.62 | 60.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.